Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

John A. Chabot

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5069911791. Sources: ClinicalTrials.gov.

Their work

Papers
38 (first author 3, last author 5)
Trials
1
Grants
0
Labs led
2
Collaborators
97
Papers, trials and grants by year

1999: 1 trial · 2000: none · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 2 papers · 2012: 2 papers · 2013: 2 papers · 2014: 6 papers · 2015: 3 papers · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 3 papers · 2024: 4 papers · 2025: 2 papers · 2026: 1 paper

Papers 38

  1. Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. Co-author DOI 10.1038/s41467-026-76559-4↗
  2. Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-025-02345-5↗
  3. A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery. Co-author DOI 10.1093/oncolo/oyaf162↗
  4. Trends in the Care of Locally Advanced Pancreatic Cancer in the Modern Era of Chemotherapy. Co-author DOI 10.1002/jso.27851↗
  5. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  6. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  7. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  8. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101194↗
  9. Transfusion of salvaged red blood cells during pancreatic ductal adenocarcinoma operations. Co-author DOI 10.1093/bjs/znac393↗
  10. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-Wo… Co-author DOI 10.1093/oncolo/oyac217↗
  11. Long-term follow-up experience with adjuvant therapy after irreversible electroporation of locally advanced pancreatic cancer. Co-author DOI 10.1002/jso.27085↗
  12. Socioeconomic Predictors of Access to Care for Patients with Operatively Managed Pancreatic Cancer in New York State. Co-author DOI 10.1007/s11605-022-05320-1↗
  13. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2022.2066767↗
  14. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Co-author DOI 10.1053/j.gastro.2020.11.052↗
  15. Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elast… Co-author DOI 10.7150/thno.37965↗
  16. Dabigatran (Pradaxa) Is Safe for Extended Venous Thromboembolism Prophylaxis After Surgery for Pancreatic Cancer. Co-author DOI 10.1007/s11605-018-3936-1↗
  17. Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1053/j.seminoncol.2018.12.002↗
  18. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Co-author DOI 10.1136/gutjnl-2018-317706↗
  19. Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. Last author DOI 10.1007/s11605-017-3556-1↗
  20. Transcriptional deconvolution reveals consistent functional subtypes of pancreatic cancer epithelium and stroma Co-author DOI 10.1101/288779↗
  21. Can diffusion-weighted imaging serve as a biomarker of fibrosis in pancreatic adenocarcinoma? Last author DOI 10.1002/jmri.25581↗
  22. Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma". Co-author DOI 10.1158/1078-0432.ccr-16-2070↗
  23. Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients. Last author DOI 10.1245/s10434-015-5034-x↗
  24. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable p… Co-author DOI 10.1002/cncr.29112↗
  25. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1053/j.seminoncol.2014.12.008↗
  26. Pancreatic cancer surgery and nutrition management: a review of the current literature. Co-author DOI 10.3978/j.issn.2304-3881.2014.08.07↗
  27. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Co-author DOI 10.1002/cncr.28662↗
  28. Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy: shifting the survival curve for patients with locally advanced pancreatic cancer. Co-author DOI 10.1007/s00268-013-2384-z↗
  29. Positron emission tomography (PET) has limited utility in the staging of pancreatic adenocarcinoma. Co-author DOI 10.1007/s11605-014-2529-x↗
  30. Absence of pancreatic intraepithelial neoplasia predicts poor survival after resection of pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000161↗
  31. A biological basis for depression in pancreatic cancer. Last author DOI 10.1111/hpb.12201↗
  32. Routine intraoperative hepatic sonography does not affect staging or postsurgical hepatic recurrence in pancreatic adenocarcinoma. Co-author DOI 10.7863/ultra.33.1.47↗
  33. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesion… Co-author DOI 10.1158/1078-0432.ccr-12-3020↗
  34. Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study. Co-author DOI 10.3109/07357907.2013.789904↗
  35. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer. First author DOI 10.1097/ppo.0b013e318279aade↗
  36. Resectable pancreatic cancer: is surgery the best first step? First author DOI 10.6092/1590-8577/697↗
  37. Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard? First author DOI 10.1038/nrclinonc.2011.107↗
  38. Adjuvant Therapy of Pancreatic Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. Co-author PMID 21737892↗

Trials 1

  1. Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pan… Study chair NCT00003851↗

Closest collaborators

The 25 strongest of 97 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael D. Kluger · 17 shared papers, 2015–2026 · strength 2.24
  2. Beth Schrope · 13 shared papers, 2014–2026 · strength 1.67
  3. Gulam Abbas Manji · 8 shared papers, 2019–2026 · strength 1.35
  4. Susan Elaine Bates · 7 shared papers, 2017–2026 · strength 1.04
  5. Kazuki N. Sugahara · 4 shared papers, 2022–2025 · strength 0.78
  6. Jeanine M. Genkinger · 6 shared papers, 2018–2024 · strength 0.71
  7. Alexander S. Thomas · 4 shared papers, 2022–2024 · strength 0.71
  8. Wooil Kwon · 4 shared papers, 2022–2024 · strength 0.71
  9. Kenneth P. Olive · 5 shared papers, 2018–2026 · strength 0.60
  10. Alexander Grenander Raufi · 3 shared papers, 2019–2026 · strength 0.51
  11. Paul E. Oberstein · 5 shared papers, 2013–2025 · strength 0.51
  12. Alina Cornelia Iuga · 4 shared papers, 2018–2026 · strength 0.43
  13. Elizabeth M. Hecht · 5 shared papers, 2015–2023 · strength 0.41
  14. Michael S. May · 2 shared papers, 2025–2026 · strength 0.37
  15. Benjamin Izar · 2 shared papers, 2025–2026 · strength 0.37
  16. Ana Babić · 3 shared papers, 2021–2024 · strength 0.35
  17. Andrea J. Bullock · 3 shared papers, 2021–2024 · strength 0.35
  18. Ehsan Irajizad · 3 shared papers, 2021–2024 · strength 0.35
  19. Thomas E. Clancy · 3 shared papers, 2021–2024 · strength 0.35
  20. Kimmie Ng · 3 shared papers, 2021–2024 · strength 0.35
  21. Johannes Francois Fahrmann · 3 shared papers, 2021–2024 · strength 0.35
  22. Brian Matthew Wolpin · 3 shared papers, 2021–2024 · strength 0.35
  23. Samir Hanash · 3 shared papers, 2021–2024 · strength 0.35
  24. Anirban Maitra · 3 shared papers, 2021–2024 · strength 0.35
  25. Kunal Jajoo · 3 shared papers, 2021–2024 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.